Why Indivior’s Once?Monthly Sublocade shot is changing opioid treatment routines
19.06.2026 - 08:54:29 | ad-hoc-news.de
Reviewed: ad hoc news Lifestyle & Consumer desk. Edited and checked on 2026-06-19, 08:53. Details in the imprint.
Sublocade from Indivior is one of those medicines you do not notice on the street, yet it can quietly reshape everyday life for people with opioid use disorder. Instead of swallowing buprenorphine tablets or films every morning, patients get a single injection that slowly releases the drug over a whole month.
Background on the Indivior PLC stock
Indivior builds much of its strategy around long-acting addiction treatments like Sublocade, which increasingly shape how analysts and investors judge the company’s growth prospects.
How Sublocade works in practice
Sublocade is a once-monthly, extended-release buprenorphine injection given only by healthcare professionals into the abdominal subcutaneous tissue. After injection, the drug forms a solid depot under the skin and slowly releases buprenorphine over several weeks.
Patients must be stabilized on daily transmucosal buprenorphine first, usually for at least seven days, before switching to Sublocade, which reduces the risk of precipitated withdrawal. The labeled starting dose is typically 300 mg monthly, with some patients stepping down to 100 mg once they are stable.
What patients and doctors feel day to day
In everyday life, the switch from a morning film or tablet to Sublocade can feel both freeing and exposing. There is no longer a daily ritual of putting a strip under the tongue, but there is the monthly clinic visit, the injection, and the discreet but palpable lump under the skin as the depot sits there.
For many, that trade-off is worth it. The steady buprenorphine levels are designed to curb cravings around the clock and lower the chance of missed doses or diversion, which has been a persistent worry with some take-home formulations. On the flip side, anyone nervous about injections or with limited clinic access may find the dependence on scheduled visits frustrating.
The clinical data behind the promise
Indivior backed Sublocade with pivotal phase 3 trials that showed statistically significant improvements in opioid-free urine samples versus placebo when added to counseling. In one key study of moderate to severe opioid use disorder, patients on the 300/100 mg regimen achieved higher rates of abstinence over 24 weeks than those on placebo.
Regulators in the United States approved Sublocade in 2017 for adults with moderate to severe opioid use disorder who have initiated treatment with a transmucosal buprenorphine-containing product. Health Canada and other regulators have since granted similar approvals, cementing the product’s role as a long-acting option in medication-assisted treatment.
Safety profile and practical downsides
The safety profile of Sublocade largely mirrors that of other buprenorphine products, with common side effects including constipation, nausea, headaches, and injection-site reactions. The depot technology introduces extra local issues, such as pain, itching, or nodules at the injection site, which some patients notice for days.
A boxed warning in the US label underlines that Sublocade must not be injected into a vein because the solidifying depot could cause serious harm if it reaches the bloodstream. Because of those risks, Sublocade is available under a controlled distribution program in some markets, which protects safety but also adds paperwork and administrative friction for clinics.
Pricing, access, and who gets it
Sublocade sits in a high-price segment compared with generic buprenorphine-naloxone films, reflecting both the extended-release technology and Indivior’s positioning in the US reimbursement system. Payers often require prior authorization, and coverage terms vary, which can make the path from prescription to first injection bumpy for patients.
The product is primarily used in North America, where the opioid crisis and willingness to fund medication-assisted treatment create a receptive environment. In Europe, national reimbursement decisions and competing long-acting formulations mean adoption is more uneven, and in Germany availability is still limited compared with classic substitution therapies like methadone.
Why Sublocade matters for Indivior
For Indivior, Sublocade is more than a niche option - it is a central pillar in the shift from older daily formulations toward long-acting, patent-protected therapies. The company highlights growing Sublocade net revenue and patient numbers as a key driver in its recent financial presentations.
Shares of Indivior PLC (GB00BYZ0C031) trade in the United States on Nasdaq under the ticker INDV, giving US investors direct exposure to the company’s addiction-treatment franchise.
Key facts on Sublocade at a glance
- Product: Sublocade
- Manufacturer: Indivior PLC
- Category: Lifestyle/Consumer (prescription medicine for opioid use disorder)
- Launch: US FDA approval in 2017
- RRP / Price: High-cost, prescription-only therapy; exact price depends on market and payer contracts
- Availability: Primarily North America and selected international markets via specialist clinics and addiction-treatment centers
- Target group: Adults with moderate to severe opioid use disorder stabilized on transmucosal buprenorphine
- Highlight / USP: Once-monthly extended-release buprenorphine injection aimed at reducing daily dosing burden and diversion risk
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
